source
- Vertex halts mRNA cystic fibrosis program citing tolerability concernsVertex Pharmaceuticals announced it is ending development of its mRNA-based cystic fibrosis therapy after encountering tolerability problems that echo challenges seen elsewhere in the field. The B…
- FDA narrows search for new CBER chief to three or four finalistsThe FDA announced that its search for a new head of the Center for Biologics Evaluation and Research (CBER) has been narrowed. According to a source familiar with the process, the agency is now fo…